Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 10 2023
11 10 2023
Historique:
received:
26
03
2023
accepted:
03
10
2023
medline:
2
11
2023
pubmed:
12
10
2023
entrez:
11
10
2023
Statut:
epublish
Résumé
Dermatomyositis and polymyositis are rare, idiopathic inflammatory myopathies. Interstitial lung disease is one of the most common and potentially severe extra-muscular manifestations of dermatomyositis and polymyositis and is strongly linked to poor prognosis and early mortality. We aimed to characterise the demographic and clinical characteristics, incidence, and treatment of interstitial lung disease in patients with dermatomyositis or polymyositis. We conducted a retrospective cohort study using the Japan Medical Data Center healthcare claims database. Patients in the database with dermatomyositis (International Classification of Disease version 10 M33.0, M33.1, M33.9) or polymyositis (M33.2) from 01-Jan-2011 until 31-Dec-2019 were identified and followed-up for interstitial lung disease (J84.x) until death, dis-enrolment, or study end (31 December 2020). Cumulative risk curves compared interstitial lung disease risk in dermatomyositis versus polymyositis. Risk factors were evaluated by Cox proportional hazard models. There were 886 patients with dermatomyositis and 745 patients with polymyositis included in the cohort analysis. Mean (standard deviation) age at dermatomyositis/polymyositis diagnosis was 46.0 (16.0)/49.7 (13.3) years and 300 (34%)/104 (14%) developed interstitial lung disease during follow-up. The incidence rate of interstitial lung disease per 100 person-years was 18.42 (95% CI 16.42-20.59) for dermatomyositis and 5.39 (95% CI 4.43-6.50) for polymyositis. In the analysis adjusted for sex, age, and comorbidity score, the risk of interstitial lung disease was significantly higher in patients with dermatomyositis than with polymyositis (hazard ratio 2.72, 95% CI 2.18-3.41). The rate diverged markedly between the groups in the first year after diagnosis. Risk factors for interstitial lung disease were older age in dermatomyositis, female sex and rheumatoid arthritis in polymyositis. Glucocorticoids with/without tacrolimus were the most common newly prescribed drugs after the interstitial lung disease diagnosis. In conclusion, the risk of developing interstitial lung disease was significantly higher in patients with dermatomyositis than with polymyositis, and risk factors were different in the 2 patient groups.
Identifiants
pubmed: 37821555
doi: 10.1038/s41598-023-44092-9
pii: 10.1038/s41598-023-44092-9
pmc: PMC10567809
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17172Informations de copyright
© 2023. Springer Nature Limited.
Références
Qudsiya Z, Waseem M. Dermatomyositis. In. StatPearls. Treasure Island (FL); 2020.
Callen, J. P. Dermatomyositis. Lancet 355(9197), 53–57 (2000).
doi: 10.1016/S0140-6736(99)05157-0
pubmed: 10615903
Jacobson, D. L., Gange, S. J., Rose, N. R. & Graham, N. M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84(3), 223–243 (1997).
doi: 10.1006/clin.1997.4412
pubmed: 9281381
Ogawa-Momohara, M. et al. Clinical characteristics of anti-Ro52α and anti-Ro52β antibodies in dermatomyositis/polymyositis. J. Dermatol. Sci. 96(1), 50–52 (2019).
doi: 10.1016/j.jdermsci.2019.08.002
pubmed: 31444014
Betteridge, Z. et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J. Autoimmun. 101, 48–55 (2019).
doi: 10.1016/j.jaut.2019.04.001
pubmed: 30992170
pmcid: 6580360
Dobloug, C. et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann. Rheum. Dis. 74(8), 1551–1556 (2015).
doi: 10.1136/annrheumdis-2013-205127
pubmed: 24695011
Chen, I. J. et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin. Rheumatol. 28(6), 639–646 (2009).
doi: 10.1007/s10067-009-1110-6
pubmed: 19247576
Ikeda, S. et al. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: A retrospective cohort study. Springerplus 4, 240 (2015).
doi: 10.1186/s40064-015-1013-8
pubmed: 26101728
pmcid: 4474966
Cho, S. K. et al. Incidence and prevalence of idiopathic inflammatory myopathies in Korea: A nationwide population-based study. J. Korean Med. Sci. 34(8), e55 (2019).
doi: 10.3346/jkms.2019.34.e55
pubmed: 30833879
pmcid: 6393764
Zhang, L. et al. Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: A systematic review and meta-analysis. PLoS ONE 11(5), e0155381 (2016).
doi: 10.1371/journal.pone.0155381
pubmed: 27171228
pmcid: 4865124
Kawasumi, H., Gono, T., Kawaguchi, Y. & Yamanaka, H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin. Med. Insights. Circ. Respir. Pulm. Med. 9(Suppl 1), 9–17 (2015).
pubmed: 26279636
pmcid: 4514184
Vacchi, C. et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. A narrative review. J. Clin. Med. 9(2), 407 (2020).
doi: 10.3390/jcm9020407
pubmed: 32028635
pmcid: 7073957
Ministry of Health Labour and Welfare Japan. Guidelines for the treatment of polymyositis and dermatomyositis (2020).
Sun, K. Y., Fan, Y., Wang, Y. X., Zhong, Y. J. & Wang, G. F. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020. Semin. Arthritis Rheum. 51(1), 175–191 (2020).
doi: 10.1016/j.semarthrit.2020.11.009
pubmed: 33383294
Ng, K. H. et al. Risk of interstitial lung disease in patients with newly diagnosed systemic autoimmune rheumatic disease: A nationwide, population-based cohort study. Semin. Arthritis Rheum. 50(5), 840–845 (2020).
doi: 10.1016/j.semarthrit.2020.07.011
pubmed: 32896697
Ohta, A., Nagai, M., Nishina, M., Tomimitsu, H. & Kohsaka, H. Prevalence and incidence of polymyositis and dermatomyositis in Japan. Mod. Rheumatol. 24(3), 477–480 (2014).
doi: 10.3109/14397595.2013.844308
pubmed: 24252012
Quan, H. et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care 43, 1130–1139 (2005).
doi: 10.1097/01.mlr.0000182534.19832.83
pubmed: 16224307
American Thoracic Society. ICD-10-CM Coding for interstitial lung diseases. 11 May 2022.
Ulm, K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am. J. Epidemiol. 131(2), 373–375 (1990).
doi: 10.1093/oxfordjournals.aje.a115507
pubmed: 2296988
Wakao, R. et al. Data-driven identification of adverse event reporting patterns for japan in vigibase, the WHO global database of individual case safety reports. Drug. Saf. 42(12), 1487–1498 (2019).
doi: 10.1007/s40264-019-00861-y
pubmed: 31559542
pmcid: 6858382
Saito, S., Lasky, J. A., Hagiwara, K. & Kondoh, Y. Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective. Respir. Investig. 56(5), 375–383 (2018).
doi: 10.1016/j.resinv.2018.06.002
pubmed: 30061050
Beom, S. H. et al. Gefitinib-induced interstitial lung disease in Korean lung cancer patients. Cancer Res. Treat. 48(1), 88–97 (2016).
doi: 10.4143/crt.2014.201
pubmed: 25761482
Kohsaka, H. et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. J. Dermatol. 46(1), e1–e18 (2019).
doi: 10.1111/1346-8138.14604
pubmed: 30562845
e-Stat. Portal Site of Official Statistics of Japan. 2020 Population Census. Statistics of Japan. (2020).